论文部分内容阅读
[目的]探讨二甲双胍对氧化偶氮甲烷(AOM)诱导的小鼠结直肠异常隐窝病灶(ACF)的预防作用,并与塞来昔布进行比较。[方法]45只6周龄BALB/c雌性小鼠随机分为对照组、二甲双胍组、塞来昔布组,每组15只;均腹腔注射AOM(10mg/kg),每周1次,连续2周以建立ACF模型;同时对照组、二甲双胍组、塞来昔布组小鼠分别予0.9%氯化钠溶液0.5ml·只~(-1)·d~(-1)、二甲双胍250mg·kg~(-1)·d~(-1)、塞来昔布20mg·kg~(-1)·d~(-1)灌胃处理,每周监测小鼠体质量变化。6周后处死小鼠并分离结直肠组织,美蓝染色后计数每只小鼠结直肠ACF个数和每个ACF中畸变隐窝(AC)个数。[结果]各组小鼠体质量随周龄增加均呈现增长趋势,干预后体质量比较均差异无统计学意义(P>0.05)。对照组小鼠结直肠ACF及AC数量分别为(8.80±0.84)个、(26.75±2.63)个,二甲双胍组分别为(3.67±0.58)个、(8.33±0.58)个,塞来昔布组分别为(5.60±0.89)个、(13.40±1.67)个;与对照组相比,二甲双胍组、塞来昔布组小鼠ACF及AC均显著减少(P<0.05);二甲双胍组小鼠ACF及AC均比塞来昔布组显著减少(P<0.05)。[结论]二甲双胍、塞来昔布均能显著抑制ACF形成,对结直肠癌起到预防的作用,且二甲双胍的作用明显优于塞来昔布。
[Objective] To investigate the preventive effect of metformin on oxidative stress induced by azomethoxy methane (AOM) in colorectal abnormal crypts (ACF) in mice and compare with celecoxib. [Method] Forty-five 6-week-old BALB / c female mice were randomly divided into control group, metformin group and celecoxib group, 15 rats in each group. All mice were injected intraperitoneally with AOM (10mg / kg) once a week 2 weeks to establish ACF model; while the control group, metformin group, celecoxib group were given 0.9% sodium chloride solution 0.5ml · -1 only, metformin 250mg · kg (-1) · d -1 and celecoxib 20 mg · kg -1 · d -1. The body weight of mice was monitored weekly. After 6 weeks, the mice were sacrificed and the colorectal tissues were separated. The number of colorectal ACF in each mouse and the number of abnormal crypts (AC) in each ACF were counted after methylene blue staining. [Result] The body weight of mice in each group increased with the increasing of age, and there was no significant difference in body weight after intervention (P> 0.05). The number of colorectal ACF and AC in the control group were (8.80 ± 0.84) and (26.75 ± 2.63), respectively, while those in metformin group were (3.67 ± 0.58) and (8.33 ± 0.58) (5.60 ± 0.89) and (13.40 ± 1.67) respectively. Compared with the control group, the ACF and AC in the metformin group and the celecoxib group were significantly decreased (P <0.05). The ACF and AC in the metformin group Compared with celecoxib group significantly reduced (P <0.05). [Conclusion] Both metformin and celecoxib can significantly inhibit the formation of ACF and play a preventive role in colorectal cancer, and the effect of metformin is better than that of celecoxib.